Hong Kong – Kirkland Represents Edding Group On Its Proposed Merger And Reverse Takeover With Genor Biopharma.

Kirkland & Ellis is representing Edding Group Company Limited, an integrated biopharmaceutical company focusing on research, development, and commercialisation of promising therapeutics in areas with considerable demand in the PRC, in connection with a proposed merger and reverse takeover with Genor Biopharma Holdings Limited, a Hong Kong-listed biopharmaceutical company under Chapter 18A that focuses on developing and commercializing oncology and immunology drugs. The deal represents the first ever reverse takeover relating to a Chapter 18A listed company and the only announced reverse takeover case in Hong Kong recently. 
 
The proposed merger is expected to bring complementary and synergetic effects to both Genor Biopharma and Edding Group, laying an important foundation for the sustainable development of the enlarged group post-merger closing.
 
The transaction is subject to customary closing conditions. 
 
Read the announcement
 
The Kirkland team is led by corporate/capital markets partner Mengyu Lu and corporate partner Joey Chau, with support from corporate/capital markets partner Ashlee Wu and corporate partner Leo Zhou. The team also includes corporate/capital markets associates Chuanwen Wang and Rock Liu and foreign legal consultant Edith Liu, corporate registered foreign lawyer Sherry Fu, legal consultant Clarence Li, legal manager Estelle Lu.